TScan Therapeutics (TCRX) Shares Outstanding (2020 - 2026)

TScan Therapeutics (TCRX) has reported Shares Outstanding (Entity) for 7 consecutive years, with $129.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Shares Outstanding (Entity) changed 0.18% year-over-year to $129.9 million; the TTM figure through Mar 2026 stood at $129.9 million (changed 0.18% YoY), while the FY2025 annual figure was $129.8 million, up 15.88% from the prior year.
• Shares Outstanding (Entity) steadied at $129.9 million in Q1 2026 per TCRX's latest filing, from $129.8 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $129.9 million in Q1 2026 and bottomed at $19.5 million in Q1 2023.
• Historically, Shares Outstanding (Entity) has averaged $82.8 million across 5 years, with a median of $94.9 million in 2024.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) surged 1737.43% — and 2023, when it decreased 18.74%.
• TScan Therapeutics' Shares Outstanding (Entity) stood at $24.0 million in 2022, then jumped by 172.78% to $65.6 million in 2023, then jumped by 70.72% to $112.0 million in 2024, then increased by 15.88% to $129.8 million in 2025, then advanced by 0.1% to $129.9 million in 2026.
• Business Quant data shows TCRX's Shares Outstanding (Entity) at $129.9 million in Q1 2026, $129.8 million in Q4 2025, and $129.8 million in Q3 2025.